At this point, only vaccine efficacy (VE) data is available since “effectiveness” depends on many different factors and requires a longer observation period.
1. AstraZeneca COVID-19 Vaccine (ChAdOx1-S [recombinant]): 70.4% (95% CI 54.8 to 80.6%) overall VE against symptomatic COVID-19, 14 days after 2nd dose
2. Sinovac CoronaVac: 65 to 91% (based on Brazil, Indonesia and Turkey Trials)
3. Gamaleya Sputnik V: 91.6% (95% CI 85.6 to 95.2%) overall VE against symptomatic COVID-19, 21 days after 1st dose; 100% (96% CI 94.4 to 100.0%) VE against moderate or severe cases, 21 days after the 1st dose
4. Janssen: 66.9% (95% CI 59.0 to 73.4%) against confirmed moderate to severe/critical COVID-19, 14 days after vaccination; 66.1% (95% CI 55.0 to 74.8%) against confirmed moderate to severe/critical COVID-19, 28 days after vaccination; ~77% effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85% effective in preventing severe/critical COVID-19 occurring at least 28 days after vaccination
5. Bharat BioTech: 80.6% (95% CI 78.1 to 82.7%) overall VE against PCR-confirmed symptomatic COVID-19, after the 2nd dose
6. Pfizer-BioNTech (BNT162b2): 95% (94.7%, 95% CI 90.3 to 97.6%) against symptomatic COVID-19, 7 days after 2nd dose
7. Moderna (mRNA-1273): 94.1% (95% CI 89.3 to 96.8%%) overall VE against symptomatic COVID-19, at least 14 days after the 2nd dose; 100% VE against severe COVID-19
Comments